The Contingent Liability Revaluation Wave
Across 2 sectors, 2 of 4 filers are signaling falling strategic moves. Visible since 2024Q1, with activity continuing through 2025Q4. Primarily a capital story (50%), with a strategic overlay (50%). One disclosure notes "$3,021 million related to the remeasurement of our contingent consideration liability to fair value in conjunction with our acquisition of fairlife." Continuing to spread to more sectors.
Pharmaceutical and consumer-goods acquirers are experiencing significant balance-sheet swings from fair-value remeasurement of contingent consideration (earnouts, CVRs) tied to past M&A deals, driven by discount-rate and time-passage effects.
DISTINCT NEW FILERS PER QUARTER
✦ WHAT THE DIFF CAUGHT
Signal mix shifts from falling (ABT gain) to rising (ABBV loss) to neutral (JNJ) — showing that direction depends on discount-rate trajectory and remaining earn-out duration, not a uniform directional trend.
REPRESENTATIVE SIGNAL FROM FILINGS
“$3,021 million related to the remeasurement of our contingent consideration liability to fair value in conjunction with our acquisition of fairlife”
The company recorded $3,021 million in charges from revaluing contingent consideration liability related to the fairlife acquisition at fair value.
“favorable change in the fair value of contingent consideration liabilities”
A favorable change in the fair value of contingent consideration liabilities contributed positively to results.
DRIVERS